Loading…
Binding of cytokines to pharmaceutically prepared human immunoglobulin
Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta wa...
Saved in:
Published in: | The Journal of clinical investigation 1993-11, Vol.92 (5), p.2533-2539 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543 |
---|---|
cites | |
container_end_page | 2539 |
container_issue | 5 |
container_start_page | 2533 |
container_title | The Journal of clinical investigation |
container_volume | 92 |
creator | SVENSON, M HANSEN, M. B BENDTZEN, K |
description | Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines. |
doi_str_mv | 10.1172/jci116862 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288439</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76048630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</originalsourceid><addsrcrecordid>eNpVkUtLxDAUhYMoOj4W_gChCxFcVPNqEhcudHB0RHCj63CbpjPRNqlJK8y_tzLDoKsD93z3wbkInRJ8RYik1x_GESKUoDtoQopC5YoytYsmGFOS30imDtBhSh8YE84Lvo_2FaWSCTFBs3vnK-cXWagzs-rDp_M2ZX3IuiXEFowdemegaVZZF20H0VbZcmjBZ65tBx8WTSiHxvljtFdDk-zJRo_Q--zhbfqUv7w-zqd3L7nhgvd5USkKEtdSWSiJxMqWgDkBYq0woi4ZhbpQhRKjEBiLUjBipZBclFwVnB2h2_XcbihbWxnr-wiN7qJrIa50AKf_O94t9SJ8a6oUZzdj_8WmP4avwaZety4Z2zTgbRiSlgJzJRgewcs1aGJIKdp6u4Ng_Zu5fp7O15mP7Nnfo7bkJuTRP9_4kMYs6wjeuLTFmGJ4_Ar7ATr5ivU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76048630</pqid></control><display><type>article</type><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><source>Free E-Journal (出版社公開部分のみ)</source><source>PubMed Central</source><creator>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</creator><creatorcontrib>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</creatorcontrib><description>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/jci116862</identifier><identifier>PMID: 8227366</identifier><identifier>CODEN: JCINAO</identifier><language>eng</language><publisher>Ann Arbor, MI: American Society for Clinical Investigation</publisher><subject>Animals ; Antibodies - blood ; Biological and medical sciences ; Biological Products - immunology ; Cytokines - immunology ; Detergents - pharmacology ; Humans ; Immunoglobulin G - immunology ; Immunomodulators ; Interleukin-1 - immunology ; Interleukin-6 - immunology ; Medical sciences ; Milk ; Pharmacology. Drug treatments ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>The Journal of clinical investigation, 1993-11, Vol.92 (5), p.2533-2539</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288439/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288439/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3830454$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8227366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SVENSON, M</creatorcontrib><creatorcontrib>HANSEN, M. B</creatorcontrib><creatorcontrib>BENDTZEN, K</creatorcontrib><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</description><subject>Animals</subject><subject>Antibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Biological Products - immunology</subject><subject>Cytokines - immunology</subject><subject>Detergents - pharmacology</subject><subject>Humans</subject><subject>Immunoglobulin G - immunology</subject><subject>Immunomodulators</subject><subject>Interleukin-1 - immunology</subject><subject>Interleukin-6 - immunology</subject><subject>Medical sciences</subject><subject>Milk</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNpVkUtLxDAUhYMoOj4W_gChCxFcVPNqEhcudHB0RHCj63CbpjPRNqlJK8y_tzLDoKsD93z3wbkInRJ8RYik1x_GESKUoDtoQopC5YoytYsmGFOS30imDtBhSh8YE84Lvo_2FaWSCTFBs3vnK-cXWagzs-rDp_M2ZX3IuiXEFowdemegaVZZF20H0VbZcmjBZ65tBx8WTSiHxvljtFdDk-zJRo_Q--zhbfqUv7w-zqd3L7nhgvd5USkKEtdSWSiJxMqWgDkBYq0woi4ZhbpQhRKjEBiLUjBipZBclFwVnB2h2_XcbihbWxnr-wiN7qJrIa50AKf_O94t9SJ8a6oUZzdj_8WmP4avwaZety4Z2zTgbRiSlgJzJRgewcs1aGJIKdp6u4Ng_Zu5fp7O15mP7Nnfo7bkJuTRP9_4kMYs6wjeuLTFmGJ4_Ar7ATr5ivU</recordid><startdate>19931101</startdate><enddate>19931101</enddate><creator>SVENSON, M</creator><creator>HANSEN, M. B</creator><creator>BENDTZEN, K</creator><general>American Society for Clinical Investigation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19931101</creationdate><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><author>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Antibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Biological Products - immunology</topic><topic>Cytokines - immunology</topic><topic>Detergents - pharmacology</topic><topic>Humans</topic><topic>Immunoglobulin G - immunology</topic><topic>Immunomodulators</topic><topic>Interleukin-1 - immunology</topic><topic>Interleukin-6 - immunology</topic><topic>Medical sciences</topic><topic>Milk</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SVENSON, M</creatorcontrib><creatorcontrib>HANSEN, M. B</creatorcontrib><creatorcontrib>BENDTZEN, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SVENSON, M</au><au>HANSEN, M. B</au><au>BENDTZEN, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Binding of cytokines to pharmaceutically prepared human immunoglobulin</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1993-11-01</date><risdate>1993</risdate><volume>92</volume><issue>5</issue><spage>2533</spage><epage>2539</epage><pages>2533-2539</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><coden>JCINAO</coden><abstract>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</abstract><cop>Ann Arbor, MI</cop><pub>American Society for Clinical Investigation</pub><pmid>8227366</pmid><doi>10.1172/jci116862</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 1993-11, Vol.92 (5), p.2533-2539 |
issn | 0021-9738 1558-8238 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288439 |
source | Free E-Journal (出版社公開部分のみ); PubMed Central |
subjects | Animals Antibodies - blood Biological and medical sciences Biological Products - immunology Cytokines - immunology Detergents - pharmacology Humans Immunoglobulin G - immunology Immunomodulators Interleukin-1 - immunology Interleukin-6 - immunology Medical sciences Milk Pharmacology. Drug treatments Tumor Necrosis Factor-alpha - immunology |
title | Binding of cytokines to pharmaceutically prepared human immunoglobulin |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Binding%20of%20cytokines%20to%20pharmaceutically%20prepared%20human%20immunoglobulin&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=SVENSON,%20M&rft.date=1993-11-01&rft.volume=92&rft.issue=5&rft.spage=2533&rft.epage=2539&rft.pages=2533-2539&rft.issn=0021-9738&rft.eissn=1558-8238&rft.coden=JCINAO&rft_id=info:doi/10.1172/jci116862&rft_dat=%3Cproquest_pubme%3E76048630%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76048630&rft_id=info:pmid/8227366&rfr_iscdi=true |